AbClon Inc.
Financials
Valuation Metrics
AbClon Inc.'s Market Cap is ₩5367B. At end of 2025 it was ₩8480B. Ranked #458 of 2,419 in KR market (top 19%), #170 of 1,638 on KOSDAQ (top 10%), #50 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 536.71B KRW | KR#458/2,419 Sec#50/231 |
| Revenue | 5.31B KRW | KR#2,336/2,419 Sec#194/231 |
| Net Income | -17.30B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 64.50B KRW | KR#2,062/2,419 Sec#176/231 |
| Net Assets | 53.07B KRW | KR#1,868/2,419 Sec#159/231 |
| Employees | 63 | KR#1,939/2,419 Sec#171/231 |
| Value | ||
| P/B | 10.11x | KR#2,346/2,419 Sec#208/231 |
| P/S | 101.12x | KR#2,388/2,419 Sec#208/231 |
| FCF Yield | -2.69% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -32.60% | KR#2,202/2,419 Sec#182/231 |
| ROA | -26.82% | KR#2,295/2,419 Sec#194/231 |
| Op. Margin | -336.22% | KR#2,348/2,419 Sec#196/231 |
| Revenue Growth | 75.02% | KR#127/2,419 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 21.54% | KR#404/2,419 Sec#49/231 |
| Total Debt | 7.00B KRW | KR#1,720/2,419 Sec#159/231 |
| FCF | -14.42B KRW | KR#1,809/2,419 Sec#167/231 |
| Cash | 30.38B KRW | KR#1,004/2,419 Sec#68/231 |
| Current Ratio | 3.89x | KR#402/2,419 Sec#63/231 |
| Performance | ||
| 1Y Return | 39.45% | KR#287/2,419 Sec#12/231 |
| 1M Return | 23.11% | KR#247/2,419 Sec#19/231 |
| From 52W High | -71.92% | KR#2,242/2,419 Sec#202/231 |
| 1Y MDD | -81.12% | KR#2,311/2,419 Sec#213/231 |
| Trading | ||
| Volume | 155,174 shares | KR#634/2,419 Sec#76/231 |
| Trading Value | 4.23B KRW | KR#413/2,419 Sec#53/231 |
| Foreign Own. | 7.73% | KR#574/2,419 Sec#47/231 |
| Per Share | ||
| EPS | -867 KRW | KR—/2,419 Sec—/231 |
| BPS | 2,660 KRW | KR#1,937/2,419 Sec#151/231 |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.